Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting. Its therapeutic use is listed as ophthalmic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Xiidra and Lifitegrastum. Its PubChem CID is 11965427.
Lifitegrast
| CAS No | 1025967-78-5 |
|---|---|
| Molecular Formula | C29H24Cl2N2O7S |
| Molecular Weight | 615.50 g/mol |
| Synonyms | (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process.
The listed CAS number is 1025967-78-5.
The listed molecular formula is C29H24Cl2N2O7S.
The listed molecular weight is 615.50 g/mol.
(2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid.
The source lists Xiidra and Lifitegrastum.